Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incytes small molecule PD-L1 inhibitor, and adagrasib, a KRASG12C selective inhibitor.
While monoclonal antibodies targeting PDL1 or PD-1 have transformed the treatment landscape in oncology, they are limited by their route of administration and long-half life and receptor occupancy which can affect the management of immune-related adverse events, said Lance Leopold, M.D., Group Vice President, Clinical Development Hematology and Oncology, Incyte. Incytes small molecule, oral PD-L1 program has shown promising safety and efficacy in early studies INCB99280s shorter half life may result in improved management of immune mediated adverse events and better clinical outcomes. We are pleased to collaborate with Mirati to conduct the first clinical trial of INCB99280 plus adagrasib, two orally-bioavailable molecules, in patients with KRASG12C-mutated solid tumors.
We are pleased to enter into this agreement with Incyte, supplying adagrasib for evaluation in combination with INCB99280, said Charles Baum, M.D., Ph.D., President, Founder and Head of Research and Development, Mirati Therapeutics, Inc. This agreement is part of our rational combination strategy for adagrasib and further demonstrates our focus to evaluate this asset in a broad range of combinations, including with novel approaches to checkpoint inhibition, to benefit people living with difficult-to-treat cancers.
Under the terms of the agreement, Incyte will initiate and sponsor the Phase 1/1b study of INCB99280 and adagrasib in patients with KRASG12C-mutated solid tumors. Mirati will supply Incyte with adagrasib for the study.